IRVINE, CA, and HERSTAL, BELGIUM – March 9, 2016 – MDxHealth SA (Euronext: MDXH.BR) announced today that it has appointed a global commercial team to drive the launch of the Company’s new non-invasive, urine-based test, SelectMDx(TM) for Prostate Cancer.
MDxHealth is employing a direct sales strategy for the SelectMDx test in the Benelux, Germany and Italy, supported by European and global distributors and commercial lab partners. The team will be led by Mr. Brett A. Swansiger, Senior Vice President of Business Development, who will oversee the global commercialization strategy for SelectMDx. The European sales team includes industry veterans, Mr. George Skinner, Senior Director European Commercial Operations, based in Germany, Mr. Harry Rentrop, Sales Director, Benelux and Dr. Maurizio Ballerini M.D., Sales Director, Italy.
Brett A. Swansiger has over 15 years of experience in oncology and autoimmune genomic and genetic testing. He joins MDxHealth from Agendia Inc. where he served as Vice President of Managed Care and Asia Market Access. Mr. Swansiger previously held positions at Prometheus Laboratories and Bristol-Myers Squibb and has successfully launched numerous oncology diagnostic tests in the U.S. and foreign markets.
George Skinner has over 30 years of experience as a sales and marketing director in the medical device and in vitro diagnostics fields. The majority of his career was spent at Gen-Probe Inc. (now Hologic), where he was responsible for the successful launch and commercialization of the company’s PCA3 product across Europe.
Harry Rentrop has over 30 years of pharmaceutical sales experience. Before joining MDxHealth, he held various senior sales positions at Roussel Laboratoria, Lederle, Yamanouchi and Astellas Pharma. His most recent position was with Noviogendix where he was responsible for the commercialization of the PCA3 service testing business in The Netherlands.
Maurizio Ballerini, M.D. has over 20 years of experience within the molecular diagnostics industry including sales and marketing positions at Abbott Laboratories and Randox Labs where he was responsible for the launch of several oncology diagnostic tests in Italy. His last position with was with Gen-Probe where he was responsible for the successful launch and widespread adoption of the PCA3 test throughout Italy.
“We are truly excited about assembling such a strong global commercial team for SelectMDx, with unparalleled commercial experience and demonstrated success in the commercialization of a molecular diagnostic test for prostate cancer across Europe,” exclaimed Dr. Jan Groen, Chief Executive Officer of MDxHealth. “I am confident our team will deliver a successful product launch of our unique non-invasive, SelectMDx for Prostate Cancer test.”
MDxHealth recently launched the SelectMDx test as a service product for hospitals, commercial labs and private clinics in the Benelux Union. The test is being performed at the Company’s state-of-the-art laboratory in Nijmegen, The Netherlands. In the first half of 2016 MDxHealth will also launch the SelectMDx for Prostate Cancer test as a CE marked in vitro diagnostic kit on the international market.
MDxHealth’s global commercialization team will be present at the EAU meeting in Munich, 11-15 March 2016 at stand A39, Hall B1. If you would like to set up a meeting, please contact: firstname.lastname@example.org.
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated side effects and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive “liquid biopsy” method to identify patients at low risk for prostate cancer, helping to both reduce unnecessary prostate biopsy procedures with their concomitant complications and expense and to identify those men at increased risk of harbouring high-grade disease who may benefit most from earlier detection.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.